Spyre Therapeutics, Inc. (SYRE) Operating cash flow 2016–2025
Spyre Therapeutics, Inc. (SYRE) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$169.3MFY2025 · since FY2016: -$18.8M → -$169.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$169.3M | -7.5% |
| FY2024 | -$157.4M | -57.6% |
| FY2023 | -$99.9M | -24.7% |
| FY2022 | -$80.1M | -49.2% |
| FY2021 | -$53.7M | +29.1% |
| FY2020 | -$75.8M | -15.3% |
| FY2019 | -$65.7M | -104.1% |
| FY2018 | -$32.2M | -30.8% |
| FY2017 | -$24.6M | -30.7% |
| FY2016 | -$18.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice